The National Institutes of Health (NIH) is reissuing the Alzheimer's Drug Development Program (ADDP) aimed at fostering innovative drug development for Alzheimer’s disease (AD). Funding under the U01 Research Project – Cooperative Agreements will support activities for preclinical and early-stage clinical development of new small-molecule and biologic candidates that can prevent, slow, or treat AD symptoms. Applications can be submitted starting January 3, 2025, with a project duration of up to five years for early-stage projects and four years for late-stage projects. Key funding activities include medicinal chemistry, pharmacokinetics, development of biomarkers, and initial Phase I clinical testing. Applicants are encouraged to align their projects with the NIH guidance on rigor and reproducibility, with an emphasis on diversity and inclusion in clinical trial participation. The application process requires compliance with extensive guidelines, detailed planning, and engagement with regulatory pathways to generate candidates eligible for FDA approval. The program aims to address the projected increase in AD cases in the U.S. and catalyze innovation in treatment solutions while ensuring a commitment to quality, compliance, and comprehensive evaluation of drug development efforts.